Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2536 to 2550 of 7687 results

  1. Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis [ID6480]

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372

    In development [GID-TA11430] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour

    In development [GID-IPG10408] Expected publication date: 16 April 2025

    Interventional procedures guidance
    In development

  4. Molnupiravir for treating COVID-19 [ID6340]

    In development [GID-TA11409] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  5. Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: Late stage assessment

    In development [GID-HTE10027] Expected publication date: 08 January 2025

    Health technology evaluations
    In development

  6. Fruquintinib for previously treated metastatic colorectal cancer ID6274

    In development [GID-TA11280] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  7. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  8. Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over [ID6140]

    In development [GID-TA11062] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Cabotegravir for preventing HIV-1 in adults and young people [ID6255]

    In development [GID-TA11304] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  10. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development [GID-TA11221] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  11. Sipavibart for preventing COVID-19 [ID6282]

    In development [GID-TA11352] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Digital front door for people accessing NHS Talking Therapies

    In development [GID-HTE10055] Expected publication date: 23 June 2025

    Health technology evaluations
    In development

  13. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]

    In development [GID-HST10061] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  14. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]

    Awaiting development [GID-TA11625] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure

    In development [GID-NG10405] Expected publication date: TBC

    NICE guideline
    In development